Enochian Biosciences Profit Margin

The latest profit margin for ENOB is -612568.11% as of March 2026. That compares with -55769.98% in the prior-year period — down 998.4% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Enochian Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, ENOB's profit margin moved from -55769.98% to -612568.11% — a 998.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Enochian Biosciences's valuation or profitability profile.

Against Healthcare companies, ENOB currently prints -612568.11% for profit margin, while the sector average sits near 14.34%. That is roughly 4270420.5% below the sector mean. Large gaps often invite a closer look at Enochian Biosciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Enochian Biosciences converts resources into returns. At -612568.11%, ENOB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -55769.98% in the prior-year period — down 998.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ENOB's profit margin (-612568.11%), review year-over-year change from -55769.98%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.